1x1 image pixel for data collection
5-Fluorouracil, 99%
5-Fluorouracil, 99%
5-Fluorouracil, 99%
Thermo Scientific Chemicals

5-Fluorouracil, 99%

5-Fluorouracil, CAS # 51-21-8, is an analogue base composed of uracil with a position 5 hydrogen fluorine substitution. | CAS: 51-21-8 | C4H3FN2O2 | 130.08 g/mol
Have Questions?
Change viewbuttonViewtableView
Quantity:
25 g
1 g
5 g
Packaging:
Glass bottle
Catalog number 228440010
Price (USD)
37.65
Special offer
Online exclusive
Ends: 26-Sep-2025
46.00
Save 8.35 (18%)
Each
In stock
Add to cart
Quantity:
1 g
Packaging:
Glass bottle
Request bulk or custom format
Price (USD)
37.65
Special offer
Online exclusive
Ends: 26-Sep-2025
46.00
Save 8.35 (18%)
Each
Add to cart
Chemical Identifiers
CAS51-21-8
IUPAC Name5-fluoro-1,2,3,4-tetrahydropyrimidine-2,4-dione
Molecular FormulaC4H3FN2O2
InChI KeyGHASVSINZRGABV-UHFFFAOYSA-N
SMILESFC1=CNC(=O)NC1=O
View more
SpecificationsSpecification SheetSpecification Sheet
Infrared spectrumConforms
Titration with NaOH98.5 to 101.0 % (On dried substance)
Heavy metals (as Pb)=<20 ppm
Sulfated ash=<0.1 %
Loss on drying=<0.5 % (80°C, 4 hrs) (in vacuum)
View more
This Thermo Scientific Chemicals brand product was originally part of the Acros Organics product portfolio. Some documentation and label information may refer to the legacy brand. The original Acros Organics product / item code or SKU reference has not changed as a part of the brand transition to Thermo Scientific Chemicals.

General Description

• 5-Fluorouracil is an antimetabolite and antineoplastic that prevents DNA synthesis by blocking conversion of deoxyuridylic acid

• 5-Fluorouracil can replace uracil in RNA and prevent protein synthesis and cell growth

Applications

• 5-Fluorouracil can be used for laboratory research on tumor growth and immunosuppression

• 5-Fluorouracil may also be appropriate for laboratory studies of neurotoxicity, cell lysis, and DNA damage

WARNING: Reproductive Harm - www.P65Warnings.ca.gov
RUO – Research Use Only

General References:

  1. Kato, K.; Shah, M.A.; Enzinger, P.; Bennouna, J.; Shen, L.; Adenis, A.; Sun, J.M.; Cho, B.C.; Özgüroğlu, M.; Kojima, T.; Kostorov, V.; Hierro, C.; Zhu, Y.; McLean, L.A.; Shah, S.; Doi, T. KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer. Future Oncol. 2019, (10), 1057-1066.
  2. Wagner, A.D.; Syn, N.L.; Moehler, M.; Grothe, W.; Yong, W.P.; Tai, B.C.; Ho, J. Unverzagt S. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev. 2017, 8(8), CD004064.

Documents & Downloads

Certificates

Safety Data Sheets

Share catalog number, name or link